Abstract:17099 Background: Prolonged infusion of gemcitabine have shown increased levels of the active triphosphate metabolite that theorically could increase the response rate and toxicity. The objectives of this study were to evaluated the efficacy and safety of this combination of using gemcitabine as a rate infusion of 10 mg/m2 per min with carboplatin in front-line chemonaive patients with advanced NSCLC. Methods: Fifty-four chemonaive patients have been included. 44 were male and 10 female. Median age was 63 years (19–75). 13% had ECOG 0 and 53.7% ECOG 1 and 33.3% ECOG 2. 32 (59.2%) patients had adenocarcinoma, 13 (24.1%) squamous cell, 1 (1.9%) large cell carcinoma, and 8 (14.8%) others. Eight (14.8%) had stage IIIB and 46 (85.2%) stage IV. Treatment was consisted of 1200 mg/m2 gemcitabine given as a 2-hour continuous infusion (10 mg/m2 per min) on days 1 and 8 of each cycle an AUC 5 carboplatin as on day 1, repeating each cycle every 21 days. A total of 223 chemotherapy cycles were administered, with a median of 4 cycles per patient (range 1–6), and 15 (27.8%) patients received all six cycles. Results: Of the fifty-four patients enrolled, all were evaluated for toxicity (according to the WHO scale) and 51 assessed for response (according to the RECIST criteria), the overall response rate (ORR) was 41.2% (95% confidence interval, 28% to 57%), including two complete responses (CRs: 3.9%) and 19 partial responses (PRs: 37.3%). As per the intent-to-treat (ITT) analysis, the ORR was 38.9%. With a median follow-up time of 10.8 months, the median TTP was 5.0 months (range 3.7–6.3 months), median OS time was 11.5 months (range 9.9–13.1 months) and 1-year survival was 41.7% (95% CI 26% to 57%) and 2-year survival was 19.3% (4.4% to 34.2%).The main grade 3–4 toxicity consisted of neutropenia (55.6%) and thrombocytopenia (57.4%).Patients were required platelet transfusion in 27 cycles (12.1%) and haematopoietic growth factors support care in 56 (25.1%) cycles. No bleeding episodes were recorded. Grade 3 nausea/vomiting occurred in 5.6% and grade 1–2 skin rash occurred in 42.6%. Conclusions: Prolonged gemcitabine infusion combined with carboplatin is manageable tolerated and its efficacy is similar to that of other chemotherapeutic schemes used for NSCLC treatment. No significant financial relationships to disclose.

Study of Curative Effect of Infusion Gemcitabine Via Artery for 103 Cases with Advanced Cancer

Treatment of Advanced Pancreatic Cancer by Transarterial Infusion of Gemcitabine

Analysis of the Efficacy of Transcatheter Arterial Infusion Chemotherapy in the Treatment of Pancreatic Carcinoma

Clinical Observation of Gemcitabine Combined with Cisplatin As Second- or Third-Line on Patients with Advanced Triple-Negative Breast Cancer

A Meta-Analysis of Gemcitabine Containing Chemotherapy for Locally Advanced and Metastatic Pancreatic Adenocarcinoma

Clinical Research for Gemcitabine Combined with Fluorouracil in the Treatment of Advanced Ovarian Cancer Patients with Taxane and Cisplatin Resistance

Phase II Trial of a 2-Hour Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

[Efficacy of Gemcitabine-Based Chemotherapy on Advanced Pancreatic Cancer].

Transarterial Infusion with Gemcitabine and Oxaliplatin for the Treatment of Unresectable Pancreatic Cancer

Phase II Trial of a 2-H Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small-cell Lung Cancer

Inferior Survival of Advanced Pancreatic Cancer Patients Who Received Gemcitabine-Based Chemotherapy but Did Not Participate in Clinical Trials

Evaluation of Efficacy and Toxicity of Gemcitabine in Combination with Vinorelbine in Metastatic Breast Cancer Patients Previously Treated with Anthracyclines and Taxanes

[Regional intra-arterial infusion chemotherapy for pancreatic cancer: an experimental study]

Influences of China-Made Gemcitabine Plus Platinum Regimen on the Quality of Life among Patients with Advanced Non-Small Cell Lung Cancer

Intra-Arterial Infusion Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Preliminary Experience on the Safety, Efficacy, and Clinical Outcomes

Results of Treatment of Patients with Advanced Pancreatic Carcinoma Treated by Intra-arterial Chemotherapy Combined with 3-D Conformal Radiotherapy

Efficacy and Safety of Nab-Paclitaxel Plus Gemcitabine in the Treatment of Advanced Pancreatic Cancer by Transcatheter Arterial Chemotherapy

Efficacy observation of albumin-bound paclitaxel plus gemcitabine for the treatment of advanced pancreatic cancer

Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial

A Comparison Between Gemcitabine-Based Combination Chemotherapy and Gemcitabine Alone on Advanced Pancreatic Cancer:A Meta-analysis in Phase III Clinical Trials